Results 201 to 210 of about 51,890 (248)

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

open access: yes
British Journal of Haematology, EarlyView.
Frank Neumann   +13 more
wiley   +1 more source

Shared and specific molecular mechanisms of proteasome inhibitors in chemotherapy‐induced peripheral neurotoxicity

open access: yesBritish Journal of Pharmacology, EarlyView.
This study compares the molecular mechanisms of chemotherapy‐related peripheral neurotoxicity of two proteasome inhibitors, bortezomib and carfilzomib, using a multidisciplinary approach to reveal that, alongside shared effects on mitochondria structure and function, the more neurotoxic drug BTZ has specific effects on microtubules and mitochondrial ...
Federico Iseppon   +27 more
wiley   +1 more source

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway

open access: yesCancer Science, EarlyView.
This study provides the first comprehensive characterization of the functional impact, and mechanistic role of FAT4 in MM. Our findings highlight the tumor‐suppressive role of FAT4 in MM and uncover a novel mechanism by which FAT4 regulates the Hippo/YAP pathway.
Lina Zhang   +5 more
wiley   +1 more source

Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

open access: yes
British Journal of Haematology, EarlyView.
Sohaib Irfan   +2 more
wiley   +1 more source

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia

open access: yesCancer Science, EarlyView.
Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li   +10 more
wiley   +1 more source

Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

open access: yes
British Journal of Haematology, EarlyView.
Kenneth J. C. Lim   +18 more
wiley   +1 more source

A Rare Case of Cutaneous Crystal‐Storing Histiocytosis With Kappa Light Chain Restriction and Unusual BCL6 Expression

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Crystal‐storing histiocytosis (CSH) is a rare histopathologic phenomenon characterized by the accumulation of crystalline material within histiocytes, most often associated with lymphoplasmacytic or plasma cell neoplasms. Cutaneous involvement is uncommon and may present diagnostic challenges.
Liangli Wang   +8 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials

open access: yes
British Journal of Haematology, EarlyView.
Charalampos Filippatos   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy